ARS Pharmaceuticals (SPRY) Enterprise Value: 2021-2025
Historic Enterprise Value for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $705.0 million.
- ARS Pharmaceuticals' Enterprise Value fell 41.30% to $705.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.9 million, marking a year-over-year decrease of 123.55%. This contributed to the annual value of $711.3 million for FY2024, which is 138.92% up from last year.
- ARS Pharmaceuticals' Enterprise Value amounted to $705.0 million in Q3 2025, which was down 52.16% from $1.5 billion recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Enterprise Value ranged from a high of $1.5 billion in Q2 2025 and a low of -$130.5 million during Q1 2022.
- Its 3-year average for Enterprise Value is $688.0 million, with a median of $705.0 million in 2025.
- Per our database at Business Quant, ARS Pharmaceuticals' Enterprise Value crashed by 261.87% in 2022 and then skyrocketed by 906.34% in 2024.
- Over the past 5 years, ARS Pharmaceuticals' Enterprise Value (Quarterly) stood at $173.5 million in 2021, then crashed by 80.87% to $33.2 million in 2022, then spiked by 796.79% to $297.7 million in 2023, then soared by 138.92% to $711.3 million in 2024, then tumbled by 41.30% to $705.0 million in 2025.
- Its Enterprise Value was $705.0 million in Q3 2025, compared to $1.5 billion in Q2 2025 and $958.6 million in Q1 2025.